Daiichi Sankyo And Sarah Cannon Research Institute (Scri) Announced That Extended Follow-Up Data From A Phase 1/2 Trial Of Ds-7300, A Specifically Designed Potential First-In-Class B7-H3 Directed Dxd Antibody Drug Conjugate (Adc), Continues To Show Promising Durable Tumour Response In Patients With Several Types Of Heavily Pretreated Cancers Including Lung, Prostate Or Esophageal Cancer. These Data Were Presented In A Proffered Paper Session (Abstract #453O) At The European Society Of Medical Oncology (#Esmo22) Congress.B7-H3 Is Overexpressed In A Wide Range Of Cancer Types, Including Lung, Prostate And Esophageal, And Its Overexpression Has Been Shown To Correlate With Poor Prognosis In Some Cancers, Making B7-H3 A Promising Therapeutic Target.A Response Rate Of 32% (95% Ci: 24-41) Was Observed With 38 Responses (33 Confirmed; 28%; 95% Ci: 20-37) In 118 Patients With Various Solid Tumours Including Small Cell Lung Cancer (Sclc), Squamous Non-Small Cell Lung Cancer (Nsclc), Metastatic Castration-Resistant Prostate Cancer (Crpc), Esophageal Squamous Cell Carcinoma (Escc), Head And Neck Squamous Cell Carcinoma (Hnscc) Or Endometrial Cancer Receiving Doses Of Ds-7300 Ranging From 4.8 Mg/Kg To 16.0 Mg/Kg.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!